MRUS Merus N.V.

15.16
+0.34  (+2%)
Previous Close 14.82
Open 14.63
Price To Book 3.84
Market Cap 440,184,244
Shares 29,035,900
Volume 67,197
Short Ratio
Av. Daily Volume 121,984
Stock charts supplied by TradingView

NewsSee all news

  1. Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates

    – MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers –– MCLA-117 demonstrates limited clinical activity in Phase 1 trial –– Extensive

  2. Merus Announces Financial Results for the First Quarter and Provides Business Update

    MCLA-128, zenocutuzumab, Phase 1/2 eNRGy trial remains on track MCLA-117 program update to be presented at upcoming medical meeting Anand Mehra, M.D. to succeed Russell Greig, Ph.D. as Chairman and Paolo Pucci

  3. Merus N.V.: Throsby Mark (EVP & Chief Scientific Officer) Sells 368 @ Avg Price: $10.93 (Form4)

  4. Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific

  5. ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region

    VICTORIA and UTRECHT, The Netherlands, Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due May 29, 2020 at ASCO but does not plan to initiate a Phase 3 trial.
MCLA-128
Breast cancer - HER2-positive MBC and ER+/HER2-low MBC
Phase 1/2 interim data due by end of 2020.
MCLA-128
Solid tumors - NRG1
Phase 1 interim data due at EHA June 11-14, 2020.
MCLA-117 (EHA)
Acute Myeloid Leukemia
Phase 1 update due by end of 2020.
MCLA-158
Colorectal cancer
Phase 1 dosing has commenced - May 9, 2019.
MCLA-145
Solid tumors

Latest News

  1. Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates

    – MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers –– MCLA-117 demonstrates limited clinical activity in Phase 1 trial –– Extensive

  2. Merus Announces Financial Results for the First Quarter and Provides Business Update

    MCLA-128, zenocutuzumab, Phase 1/2 eNRGy trial remains on track MCLA-117 program update to be presented at upcoming medical meeting Anand Mehra, M.D. to succeed Russell Greig, Ph.D. as Chairman and Paolo Pucci

  3. Merus N.V.: Throsby Mark (EVP & Chief Scientific Officer) Sells 368 @ Avg Price: $10.93 (Form4)

  4. Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific

  5. ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region

    VICTORIA and UTRECHT, The Netherlands, Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery

  6. Merus Announces Chief Executive Officer Transition

    — Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer —— Ton Logtenberg, Ph.D., to step down after 16 years of leadership —— Transition to occur December 31, 2019 — UTRECHT, The Netherlands and

  7. Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage company developing innovative, full-length bispecific

  8. Merus Announces Pricing of Public Offering of Common Shares

    UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an

  9. Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the launch of a proposed

  10. Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

    Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

  11. Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage bispecific antibody company developing Biclonics®, innovative